Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03935685 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ
A Phase 2 study of Glioma of Brain, sponsored by University of California, Irvine.
- Active
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT03935685 is a Phase 2 study of Glioma of Brain that is active but no longer recruiting, run by University of California, Irvine. The registered enrollment target is 120 participants, above the 44-participant average among 3 other Glioma of Brain trials with a reported enrollment target (173% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03935685, a Phase 2 study of Glioma of Brain, is active but no longer recruiting, sponsored by University of California, Irvine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to estimate the ability of mirtazapine to reduce depression, nausea, and vomiting, and maintain weight in depressed glioma patients undergoing Temozolomide (TMZ) therapy. Of equal importance, the investigators will monitor the tolerability of Mirtazapine in these patients over the course of the study.
Conditions Studied
Interventions
- DRUG Mirtazapine (Remeron)
Study Locations (1)
California
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2019-02-26 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03935685
The ClinicalTrials.gov registry entry for NCT03935685 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 44-participant average among 3 other Glioma of Brain trials with a reported enrollment target (173% higher). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioma of Brain appearing as the primary indexed condition, and to 1 intervention - of which Mirtazapine (Remeron) is the first listed.
NCT03935685 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03935685 about?
NCT03935685 is a clinical study titled "Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ". The purpose of the study is to estimate the ability of mirtazapine to reduce depression, nausea, and vomiting, and maintain weight in depressed glioma patients undergoing Temozolomide (TMZ) therapy. Of equal importance, the investigators will monitor the tolerability of Mirtazapine in these patients...
What is the current status of trial NCT03935685?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2019-02-26. Estimated completion is 2030-12-31.
What conditions does trial NCT03935685 study?
This clinical trial studies the following conditions: Glioma of Brain.
What interventions are being tested in trial NCT03935685?
The interventions under investigation include: Mirtazapine (Remeron) (DRUG).
Who is sponsoring clinical trial NCT03935685?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03935685 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma of Brain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Utilizing Escitalopram in Glioma Patients
RECRUITING · Phase 2
-
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
RECRUITING · Phase 1
-
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.